Menu
Reference is made to the stock exchange announcement made by Thor Medical ASA on 5 May 2026 regarding issuance of 219,521 new shares to members of the board.
The share issue has now been registered in the Norwegian Register of Business Enterprises and the Company's new share capital is NOK 72,000,364 divided into 360,001,820 shares, each with a nominal value of NOK 0.20. Each share represents one vote in the Company's general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
